Skip to main content

Table 1 Profiles of patients with TAK and healthy controls

From: A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production

 

Risk group

(n = 31)

Non-risk group

(n = 13)

Healthy controls

(n = 19)

P value

Age (years)

48.1 ± 14.6

40.3 ± 12.1

35.4 ± 9.3

<0.01a

Sex (male/female)

1/30

0/11

1/18

1.00b

Duration of disease (years)

16.8 ± 11.4

15.8 ± 11.1

0.97c

Average dose of glucocorticoids (mg/day)

6.3 ± 3.5

6.3 ± 4.0

0.64c

Average CRP (mg/dL)

0.43 ± 0.77

0.14 ± 0.21

0.052c

Average ESR (mm/h)

22.6 ± 17.7

20.4 ± 20.9

0.69c

Use of immunosuppressants

8/31 (25.8%)

4/13 (30.8%)

0.73b

Use of biologics

2/31 (6.5%)

0/13 (0%)

1.00b

  1. Values are average ± standard deviation or number of patients. Immunosuppressants: methotrexate (n = 6; n = 4 in the risk group and 2 in the non-risk group) and azathioprine (n = 6; n = 4 in the risk group and 2 in the non-risk group). Biologics: tocilizumab (n = 2)
  2. TAK Takayasu arteritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate
  3. aStatistical analysis performed by one-way analysis of variance.
  4. bStatistical analysis performed by Fisher’s exact test
  5. cStatistical analysis performed by Welch’s t test